Abstract
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.
Publication types
-
Clinical Trial, Phase II
-
Comparative Study
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Central Nervous System Neoplasms / drug therapy*
-
Central Nervous System Neoplasms / mortality
-
Central Nervous System Neoplasms / radiotherapy
-
Combined Modality Therapy
-
Cranial Irradiation* / adverse effects
-
Cytarabine / administration & dosage
-
Cytarabine / adverse effects
-
Female
-
Hematologic Diseases / chemically induced
-
Humans
-
Idarubicin / administration & dosage
-
Idarubicin / adverse effects
-
Life Tables
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / mortality
-
Lymphoma, Non-Hodgkin / radiotherapy
-
Male
-
Meningeal Neoplasms / drug therapy
-
Meningeal Neoplasms / mortality
-
Meningeal Neoplasms / radiotherapy
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Middle Aged
-
Radiotherapy, Adjuvant* / adverse effects
-
Remission Induction
-
Stroke / etiology
-
Survival Analysis
-
Thiotepa / administration & dosage
-
Thiotepa / adverse effects
Substances
-
Cytarabine
-
Thiotepa
-
Methotrexate
-
Idarubicin